A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

632

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: IMVAMUNE

Sponsor

Bavarian Nordic

Collaborators

[object Object]